Fluvoxamine for COVID-19 outpatients: for the time being, we might
prefer to curb our optimism
- Vladimir Trkulja
Vladimir Trkulja
Department of Pharmacology, School of Medicine, University of Zagreb
Corresponding Author:vladimir.trkulja@mef.hr
Author Profile27 May 2022Submitted to British Journal of Clinical Pharmacology 28 May 2022Submission Checks Completed
28 May 2022Assigned to Editor
06 Jun 2022Reviewer(s) Assigned
17 Jun 2022Review(s) Completed, Editorial Evaluation Pending
20 Jun 2022Editorial Decision: Revise Minor
23 Jun 20221st Revision Received
24 Jun 2022Submission Checks Completed
24 Jun 2022Assigned to Editor
24 Jun 2022Review(s) Completed, Editorial Evaluation Pending
26 Jun 2022Editorial Decision: Accept
Oct 2022Published in British Journal of Clinical Pharmacology volume 88 issue 10 on pages 4654-4656. 10.1111/bcp.15451 
